Share Price and Basic Stock Data
Last Updated: November 3, 2025, 11:02 pm
| PEG Ratio | -7.23 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Auro Laboratories Ltd operates in the pharmaceuticals sector, with a market capitalization of ₹125 Cr and a current share price of ₹200. The company reported total sales of ₹52.89 Cr for the fiscal year ending March 2023, showing a slight increase from ₹50.87 Cr in the previous year. The revenue trends indicate fluctuations, with quarterly sales peaking at ₹17.98 Cr in December 2023 but dropping to ₹10.18 Cr in June 2023. This variability in sales can be attributed to market conditions and operational challenges. For instance, sales in the last quarter of FY2025 are projected at ₹19.40 Cr, a significant decrease from earlier periods, reflecting potential hurdles in sustaining revenue momentum. The trailing twelve months (TTM) revenue stood at ₹16.32 Cr, which indicates a decline in performance relative to the previous fiscal year’s revenue. Auro Laboratories’ ability to stabilize revenue in a competitive environment remains crucial for its long-term sustainability.
Profitability and Efficiency Metrics
The profitability metrics for Auro Laboratories reveal a challenging operational landscape. The operating profit margin (OPM) for FY2025 stood at 1.08%, significantly lower than the industry average, indicating limited pricing power or high operational costs. The net profit recorded for the same period was ₹0.69 Cr, translating to a net profit margin of approximately 9.47%. This is notably higher than the 4.61% reported in FY2023, reflecting an improvement in profitability despite the revenue decline. Return on equity (ROE) was reported at 4.33%, which is below the typical sector benchmarks, suggesting inefficiencies in utilizing equity capital. Additionally, the return on capital employed (ROCE) was 3.85%, indicating a need for improved asset utilization. The interest coverage ratio (ICR) for the company was recorded at 3.75x, demonstrating a reasonable ability to meet interest obligations, but still reflecting caution regarding overall profitability.
Balance Sheet Strength and Financial Ratios
Auro Laboratories’ balance sheet exhibits a mix of strengths and weaknesses. The total assets stood at ₹99.09 Cr as of March 2025, with total liabilities amounting to ₹99.09 Cr as well, reflecting a balanced approach to financing. Borrowings increased to ₹42.72 Cr, up from ₹26.25 Cr in FY2024, indicating a reliance on debt to fuel operations. The company’s equity capital remained stable at ₹6.23 Cr, while reserves grew to ₹36.74 Cr, showcasing a positive trend in retained earnings. The debt-to-equity ratio was reported at 1.05x, suggesting a high leverage position compared to industry norms. Furthermore, the current ratio stood at 0.99, indicating potential liquidity concerns, as it is below the generally accepted threshold of 1. This financial structure necessitates careful management to mitigate risks associated with high leverage and liquidity issues.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Auro Laboratories reveals a strong promoter presence, with promoters holding 52.17% of the total shares as of March 2025. This stability among promoters can instill confidence among investors regarding the company’s governance. The public shareholding stood at 47.82%, indicating a relatively diversified shareholder base, although foreign institutional investors (FIIs) did not have any reported stake. Domestic institutional investors (DIIs) held a mere 0.01%, which may reflect limited institutional interest. The number of shareholders has declined from 11,183 in September 2022 to 8,916 in March 2025, suggesting potential challenges in attracting new investors or retaining existing ones. This declining trend in shareholder numbers could affect market perception and investor sentiment, highlighting the importance of strategic initiatives to enhance shareholder value and engagement.
Outlook, Risks, and Final Insight
The outlook for Auro Laboratories hinges on its ability to navigate operational challenges and enhance profitability. Key strengths include a solid promoter base and improving net profit margins, which can support future growth. However, risks such as high leverage, declining sales, and liquidity concerns pose significant challenges. The company’s reliance on debt financing may exacerbate its financial strain if revenue does not stabilize. Additionally, the fluctuating sales figures indicate that Auro Laboratories must develop a more resilient operational strategy to adapt to market demands. To improve its market position, the company should focus on enhancing efficiency, optimizing costs, and potentially diversifying its product offerings. Auro Laboratories’ future performance will depend on its strategic responses to these challenges and its ability to regain investor confidence.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Auro Laboratories Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 145 Cr. | 115 | 247/84.3 | 33.0 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.63 Cr. | 1.90 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 5,079 Cr. | 464 | 479/192 | 114 | 22.8 | 0.14 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.5 Cr. | 46.5 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 35.1 Cr. | 24.0 | 29.1/17.0 | 36.6 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,966.35 Cr | 1,197.73 | 54.46 | 195.30 | 0.33% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 11.19 | 12.56 | 15.62 | 13.52 | 10.18 | 13.41 | 17.98 | 12.06 | 5.72 | 3.10 | 3.05 | 7.40 | 2.77 |
| Expenses | 10.62 | 11.54 | 15.17 | 11.17 | 9.02 | 10.38 | 13.90 | 9.65 | 4.39 | 2.38 | 2.60 | 6.59 | 2.74 |
| Operating Profit | 0.57 | 1.02 | 0.45 | 2.35 | 1.16 | 3.03 | 4.08 | 2.41 | 1.33 | 0.72 | 0.45 | 0.81 | 0.03 |
| OPM % | 5.09% | 8.12% | 2.88% | 17.38% | 11.39% | 22.60% | 22.69% | 19.98% | 23.25% | 23.23% | 14.75% | 10.95% | 1.08% |
| Other Income | 0.05 | -0.16 | 0.43 | 0.62 | 0.36 | 0.32 | 0.42 | 0.40 | 0.20 | 0.31 | 0.14 | 0.13 | 0.42 |
| Interest | 0.26 | 0.32 | 0.10 | 0.13 | 0.27 | 0.35 | 0.44 | -0.32 | 0.25 | 0.28 | 0.25 | 0.30 | 0.28 |
| Depreciation | 0.25 | 0.25 | 0.27 | 0.30 | 0.27 | 0.27 | 0.27 | 0.28 | 0.27 | 0.27 | 0.27 | 0.29 | 0.27 |
| Profit before tax | 0.11 | 0.29 | 0.51 | 2.54 | 0.98 | 2.73 | 3.79 | 2.85 | 1.01 | 0.48 | 0.07 | 0.35 | -0.10 |
| Tax % | 27.27% | 27.59% | 27.45% | 29.53% | 27.55% | 27.84% | 27.70% | 18.60% | 24.75% | 25.00% | 28.57% | -11.43% | 0.00% |
| Net Profit | 0.08 | 0.21 | 0.37 | 1.78 | 0.71 | 1.97 | 2.73 | 2.32 | 0.75 | 0.36 | 0.05 | 0.39 | -0.11 |
| EPS in Rs | 0.13 | 0.34 | 0.59 | 2.86 | 1.14 | 3.16 | 4.38 | 3.72 | 1.20 | 0.58 | 0.08 | 0.63 | -0.18 |
Last Updated: August 19, 2025, 11:00 pm
Below is a detailed analysis of the quarterly data for Auro Laboratories Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 2.77 Cr.. The value appears to be declining and may need further review. It has decreased from 7.40 Cr. (Mar 2025) to 2.77 Cr., marking a decrease of 4.63 Cr..
- For Expenses, as of Jun 2025, the value is 2.74 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 6.59 Cr. (Mar 2025) to 2.74 Cr., marking a decrease of 3.85 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.03 Cr.. The value appears to be declining and may need further review. It has decreased from 0.81 Cr. (Mar 2025) to 0.03 Cr., marking a decrease of 0.78 Cr..
- For OPM %, as of Jun 2025, the value is 1.08%. The value appears to be declining and may need further review. It has decreased from 10.95% (Mar 2025) to 1.08%, marking a decrease of 9.87%.
- For Other Income, as of Jun 2025, the value is 0.42 Cr.. The value appears strong and on an upward trend. It has increased from 0.13 Cr. (Mar 2025) to 0.42 Cr., marking an increase of 0.29 Cr..
- For Interest, as of Jun 2025, the value is 0.28 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.30 Cr. (Mar 2025) to 0.28 Cr., marking a decrease of 0.02 Cr..
- For Depreciation, as of Jun 2025, the value is 0.27 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.29 Cr. (Mar 2025) to 0.27 Cr., marking a decrease of 0.02 Cr..
- For Profit before tax, as of Jun 2025, the value is -0.10 Cr.. The value appears to be declining and may need further review. It has decreased from 0.35 Cr. (Mar 2025) to -0.10 Cr., marking a decrease of 0.45 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value appears to be increasing, which may not be favorable. It has increased from -11.43% (Mar 2025) to 0.00%, marking an increase of 11.43%.
- For Net Profit, as of Jun 2025, the value is -0.11 Cr.. The value appears to be declining and may need further review. It has decreased from 0.39 Cr. (Mar 2025) to -0.11 Cr., marking a decrease of 0.50 Cr..
- For EPS in Rs, as of Jun 2025, the value is -0.18. The value appears to be declining and may need further review. It has decreased from 0.63 (Mar 2025) to -0.18, marking a decrease of 0.81.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:51 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 33.74 | 32.65 | 27.91 | 35.47 | 40.79 | 46.82 | 43.79 | 54.25 | 50.87 | 52.89 | 53.64 | 19.40 | 16.32 |
| Expenses | 30.95 | 29.71 | 25.11 | 31.03 | 34.43 | 39.83 | 37.51 | 43.01 | 46.24 | 48.50 | 42.96 | 16.00 | 14.31 |
| Operating Profit | 2.79 | 2.94 | 2.80 | 4.44 | 6.36 | 6.99 | 6.28 | 11.24 | 4.63 | 4.39 | 10.68 | 3.40 | 2.01 |
| OPM % | 8.27% | 9.00% | 10.03% | 12.52% | 15.59% | 14.93% | 14.34% | 20.72% | 9.10% | 8.30% | 19.91% | 17.53% | 12.32% |
| Other Income | 0.06 | 0.24 | 0.42 | 0.53 | 0.51 | 0.96 | 0.97 | 0.76 | 1.09 | 0.94 | 1.50 | 0.66 | 1.00 |
| Interest | 1.53 | 1.66 | 1.66 | 1.18 | 1.21 | 0.87 | 0.58 | 0.46 | 0.83 | 0.81 | 0.74 | 1.08 | 1.11 |
| Depreciation | 0.74 | 0.72 | 0.68 | 0.86 | 0.93 | 1.01 | 1.02 | 1.04 | 1.02 | 1.07 | 1.09 | 1.10 | 1.10 |
| Profit before tax | 0.58 | 0.80 | 0.88 | 2.93 | 4.73 | 6.07 | 5.65 | 10.50 | 3.87 | 3.45 | 10.35 | 1.88 | 0.80 |
| Tax % | 0.00% | 0.00% | 0.00% | 72.01% | 25.16% | 27.51% | 27.96% | 31.62% | 26.61% | 28.99% | 24.64% | 2.13% | |
| Net Profit | 0.58 | 0.80 | 0.88 | 0.82 | 3.53 | 4.40 | 4.05 | 7.18 | 2.84 | 2.44 | 7.79 | 1.84 | 0.69 |
| EPS in Rs | 0.93 | 1.28 | 1.41 | 1.32 | 5.66 | 7.06 | 6.50 | 11.52 | 4.56 | 3.91 | 12.50 | 2.95 | 1.11 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 37.93% | 10.00% | -6.82% | 330.49% | 24.65% | -7.95% | 77.28% | -60.45% | -14.08% | 219.26% | -76.38% |
| Change in YoY Net Profit Growth (%) | 0.00% | -27.93% | -16.82% | 337.31% | -305.84% | -32.60% | 85.24% | -137.73% | 46.36% | 233.35% | -295.64% |
Auro Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -5% |
| 5 Years: | -15% |
| 3 Years: | -27% |
| TTM: | -67% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | -15% |
| 3 Years: | -13% |
| TTM: | -91% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 34% |
| 5 Years: | 33% |
| 3 Years: | 42% |
| 1 Year: | 23% |
| Return on Equity | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 13% |
| 3 Years: | 11% |
| Last Year: | 4% |
Last Updated: September 5, 2025, 2:31 pm
Balance Sheet
Last Updated: September 10, 2025, 3:06 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 |
| Reserves | 0.67 | 1.47 | 2.35 | 3.18 | 6.75 | 11.18 | 15.27 | 22.35 | 25.29 | 27.97 | 35.73 | 36.74 |
| Borrowings | 14.80 | 16.41 | 12.62 | 4.95 | 9.20 | 8.09 | 3.16 | 3.16 | 13.78 | 6.41 | 26.25 | 42.72 |
| Other Liabilities | 5.14 | 4.67 | 4.49 | 12.45 | 8.23 | 7.97 | 7.68 | 10.15 | 9.66 | 15.38 | 17.52 | 13.40 |
| Total Liabilities | 26.84 | 28.78 | 25.69 | 26.81 | 30.41 | 33.47 | 32.34 | 41.89 | 54.96 | 55.99 | 85.73 | 99.09 |
| Fixed Assets | 10.51 | 9.80 | 9.13 | 13.00 | 13.02 | 14.59 | 14.24 | 13.56 | 13.61 | 12.62 | 22.15 | 21.06 |
| CWIP | 0.06 | 0.82 | 3.33 | 0.23 | 1.07 | 0.12 | 0.12 | 0.13 | 3.68 | 7.67 | 32.68 | 56.48 |
| Investments | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |
| Other Assets | 16.22 | 18.11 | 13.18 | 13.53 | 16.27 | 18.71 | 17.93 | 28.15 | 37.62 | 35.65 | 30.85 | 21.50 |
| Total Assets | 26.84 | 28.78 | 25.69 | 26.81 | 30.41 | 33.47 | 32.34 | 41.89 | 54.96 | 55.99 | 85.73 | 99.09 |
Below is a detailed analysis of the balance sheet data for Auro Laboratories Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 6.23 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 6.23 Cr..
- For Reserves, as of Mar 2025, the value is 36.74 Cr.. The value appears strong and on an upward trend. It has increased from 35.73 Cr. (Mar 2024) to 36.74 Cr., marking an increase of 1.01 Cr..
- For Borrowings, as of Mar 2025, the value is 42.72 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 26.25 Cr. (Mar 2024) to 42.72 Cr., marking an increase of 16.47 Cr..
- For Other Liabilities, as of Mar 2025, the value is 13.40 Cr.. The value appears to be improving (decreasing). It has decreased from 17.52 Cr. (Mar 2024) to 13.40 Cr., marking a decrease of 4.12 Cr..
- For Total Liabilities, as of Mar 2025, the value is 99.09 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 85.73 Cr. (Mar 2024) to 99.09 Cr., marking an increase of 13.36 Cr..
- For Fixed Assets, as of Mar 2025, the value is 21.06 Cr.. The value appears to be declining and may need further review. It has decreased from 22.15 Cr. (Mar 2024) to 21.06 Cr., marking a decrease of 1.09 Cr..
- For CWIP, as of Mar 2025, the value is 56.48 Cr.. The value appears strong and on an upward trend. It has increased from 32.68 Cr. (Mar 2024) to 56.48 Cr., marking an increase of 23.80 Cr..
- For Investments, as of Mar 2025, the value is 0.05 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.05 Cr..
- For Other Assets, as of Mar 2025, the value is 21.50 Cr.. The value appears to be declining and may need further review. It has decreased from 30.85 Cr. (Mar 2024) to 21.50 Cr., marking a decrease of 9.35 Cr..
- For Total Assets, as of Mar 2025, the value is 99.09 Cr.. The value appears strong and on an upward trend. It has increased from 85.73 Cr. (Mar 2024) to 99.09 Cr., marking an increase of 13.36 Cr..
However, the Borrowings (42.72 Cr.) are higher than the Reserves (36.74 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -12.01 | -13.47 | -9.82 | -0.51 | -2.84 | -1.10 | 3.12 | 8.08 | -9.15 | -2.02 | -15.57 | -39.32 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 46.95 | 94.80 | 66.04 | 79.13 | 74.90 | 66.26 | 48.18 | 49.12 | 97.65 | 85.57 | 91.11 | 176.67 |
| Inventory Days | 115.33 | 89.37 | 86.72 | 21.65 | 22.00 | 42.98 | 60.54 | 32.60 | 47.32 | 120.27 | 113.24 | 145.45 |
| Days Payable | 62.97 | 56.12 | 72.03 | 80.26 | 78.26 | 66.19 | 70.67 | 73.51 | 54.12 | 117.41 | 85.34 | 246.11 |
| Cash Conversion Cycle | 99.30 | 128.05 | 80.73 | 20.52 | 18.64 | 43.05 | 38.04 | 8.20 | 90.86 | 88.44 | 119.01 | 76.01 |
| Working Capital Days | 19.15 | 39.13 | 26.68 | 67.20 | 64.70 | 63.46 | 51.09 | 29.40 | 36.59 | 104.28 | 35.86 | -14.30 |
| ROCE % | 9.43% | 10.74% | 11.21% | 23.06% | 32.51% | 29.11% | 24.84% | 38.87% | 12.20% | 9.92% | 20.38% | 3.85% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 2.95 | 12.50 | 3.92 | 4.56 | 11.52 |
| Diluted EPS (Rs.) | 2.95 | 12.50 | 3.92 | 4.56 | 11.52 |
| Cash EPS (Rs.) | 4.71 | 14.26 | 5.64 | 6.20 | 13.18 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 68.94 | 67.32 | 54.87 | 50.58 | 45.86 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 68.94 | 67.32 | 54.87 | 50.58 | 45.86 |
| Revenue From Operations / Share (Rs.) | 31.12 | 86.06 | 84.87 | 81.61 | 87.05 |
| PBDIT / Share (Rs.) | 6.51 | 19.53 | 8.56 | 9.17 | 19.25 |
| PBIT / Share (Rs.) | 4.75 | 17.78 | 6.83 | 7.54 | 17.59 |
| PBT / Share (Rs.) | 3.02 | 16.60 | 5.53 | 6.21 | 16.86 |
| Net Profit / Share (Rs.) | 2.95 | 12.50 | 3.92 | 4.56 | 11.52 |
| PBDIT Margin (%) | 20.92 | 22.69 | 10.08 | 11.24 | 22.11 |
| PBIT Margin (%) | 15.27 | 20.66 | 8.05 | 9.24 | 20.20 |
| PBT Margin (%) | 9.69 | 19.28 | 6.51 | 7.61 | 19.36 |
| Net Profit Margin (%) | 9.47 | 14.52 | 4.61 | 5.59 | 13.23 |
| Return on Networth / Equity (%) | 4.27 | 18.57 | 7.14 | 9.02 | 25.11 |
| Return on Capital Employeed (%) | 3.82 | 17.93 | 11.25 | 13.49 | 32.80 |
| Return On Assets (%) | 1.85 | 9.08 | 4.36 | 5.17 | 17.13 |
| Long Term Debt / Equity (X) | 0.76 | 0.43 | 0.05 | 0.02 | 0.07 |
| Total Debt / Equity (X) | 1.05 | 0.62 | 0.18 | 0.02 | 0.07 |
| Asset Turnover Ratio (%) | 0.20 | 0.75 | 0.95 | 1.05 | 1.46 |
| Current Ratio (X) | 0.99 | 1.29 | 1.97 | 1.87 | 3.32 |
| Quick Ratio (X) | 0.82 | 0.94 | 1.32 | 1.66 | 3.02 |
| Inventory Turnover Ratio (X) | 0.85 | 2.90 | 4.66 | 9.92 | 8.30 |
| Interest Coverage Ratio (X) | 3.75 | 16.55 | 6.55 | 6.92 | 26.18 |
| Interest Coverage Ratio (Post Tax) (X) | 2.70 | 11.59 | 4.00 | 4.44 | 16.66 |
| Enterprise Value (Cr.) | 188.07 | 125.03 | 37.80 | 50.97 | 38.05 |
| EV / Net Operating Revenue (X) | 9.70 | 2.33 | 0.71 | 1.00 | 0.70 |
| EV / EBITDA (X) | 46.33 | 10.27 | 7.09 | 8.91 | 3.17 |
| MarketCap / Net Operating Revenue (X) | 7.41 | 1.87 | 0.64 | 1.23 | 0.93 |
| Price / BV (X) | 3.34 | 2.39 | 0.99 | 1.98 | 1.77 |
| Price / Net Operating Revenue (X) | 7.41 | 1.87 | 0.64 | 1.23 | 0.93 |
| EarningsYield | 0.01 | 0.07 | 0.07 | 0.04 | 0.14 |
After reviewing the key financial ratios for Auro Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 2.95. This value is below the healthy minimum of 5. It has decreased from 12.50 (Mar 24) to 2.95, marking a decrease of 9.55.
- For Diluted EPS (Rs.), as of Mar 25, the value is 2.95. This value is below the healthy minimum of 5. It has decreased from 12.50 (Mar 24) to 2.95, marking a decrease of 9.55.
- For Cash EPS (Rs.), as of Mar 25, the value is 4.71. This value is within the healthy range. It has decreased from 14.26 (Mar 24) to 4.71, marking a decrease of 9.55.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 68.94. It has increased from 67.32 (Mar 24) to 68.94, marking an increase of 1.62.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 68.94. It has increased from 67.32 (Mar 24) to 68.94, marking an increase of 1.62.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 31.12. It has decreased from 86.06 (Mar 24) to 31.12, marking a decrease of 54.94.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 6.51. This value is within the healthy range. It has decreased from 19.53 (Mar 24) to 6.51, marking a decrease of 13.02.
- For PBIT / Share (Rs.), as of Mar 25, the value is 4.75. This value is within the healthy range. It has decreased from 17.78 (Mar 24) to 4.75, marking a decrease of 13.03.
- For PBT / Share (Rs.), as of Mar 25, the value is 3.02. This value is within the healthy range. It has decreased from 16.60 (Mar 24) to 3.02, marking a decrease of 13.58.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 2.95. This value is within the healthy range. It has decreased from 12.50 (Mar 24) to 2.95, marking a decrease of 9.55.
- For PBDIT Margin (%), as of Mar 25, the value is 20.92. This value is within the healthy range. It has decreased from 22.69 (Mar 24) to 20.92, marking a decrease of 1.77.
- For PBIT Margin (%), as of Mar 25, the value is 15.27. This value is within the healthy range. It has decreased from 20.66 (Mar 24) to 15.27, marking a decrease of 5.39.
- For PBT Margin (%), as of Mar 25, the value is 9.69. This value is below the healthy minimum of 10. It has decreased from 19.28 (Mar 24) to 9.69, marking a decrease of 9.59.
- For Net Profit Margin (%), as of Mar 25, the value is 9.47. This value is within the healthy range. It has decreased from 14.52 (Mar 24) to 9.47, marking a decrease of 5.05.
- For Return on Networth / Equity (%), as of Mar 25, the value is 4.27. This value is below the healthy minimum of 15. It has decreased from 18.57 (Mar 24) to 4.27, marking a decrease of 14.30.
- For Return on Capital Employeed (%), as of Mar 25, the value is 3.82. This value is below the healthy minimum of 10. It has decreased from 17.93 (Mar 24) to 3.82, marking a decrease of 14.11.
- For Return On Assets (%), as of Mar 25, the value is 1.85. This value is below the healthy minimum of 5. It has decreased from 9.08 (Mar 24) to 1.85, marking a decrease of 7.23.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.76. This value is within the healthy range. It has increased from 0.43 (Mar 24) to 0.76, marking an increase of 0.33.
- For Total Debt / Equity (X), as of Mar 25, the value is 1.05. This value exceeds the healthy maximum of 1. It has increased from 0.62 (Mar 24) to 1.05, marking an increase of 0.43.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.20. It has decreased from 0.75 (Mar 24) to 0.20, marking a decrease of 0.55.
- For Current Ratio (X), as of Mar 25, the value is 0.99. This value is below the healthy minimum of 1.5. It has decreased from 1.29 (Mar 24) to 0.99, marking a decrease of 0.30.
- For Quick Ratio (X), as of Mar 25, the value is 0.82. This value is below the healthy minimum of 1. It has decreased from 0.94 (Mar 24) to 0.82, marking a decrease of 0.12.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.85. This value is below the healthy minimum of 4. It has decreased from 2.90 (Mar 24) to 0.85, marking a decrease of 2.05.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 3.75. This value is within the healthy range. It has decreased from 16.55 (Mar 24) to 3.75, marking a decrease of 12.80.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.70. This value is below the healthy minimum of 3. It has decreased from 11.59 (Mar 24) to 2.70, marking a decrease of 8.89.
- For Enterprise Value (Cr.), as of Mar 25, the value is 188.07. It has increased from 125.03 (Mar 24) to 188.07, marking an increase of 63.04.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 9.70. This value exceeds the healthy maximum of 3. It has increased from 2.33 (Mar 24) to 9.70, marking an increase of 7.37.
- For EV / EBITDA (X), as of Mar 25, the value is 46.33. This value exceeds the healthy maximum of 15. It has increased from 10.27 (Mar 24) to 46.33, marking an increase of 36.06.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 7.41. This value exceeds the healthy maximum of 3. It has increased from 1.87 (Mar 24) to 7.41, marking an increase of 5.54.
- For Price / BV (X), as of Mar 25, the value is 3.34. This value exceeds the healthy maximum of 3. It has increased from 2.39 (Mar 24) to 3.34, marking an increase of 0.95.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 7.41. This value exceeds the healthy maximum of 3. It has increased from 1.87 (Mar 24) to 7.41, marking an increase of 5.54.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.07 (Mar 24) to 0.01, marking a decrease of 0.06.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Auro Laboratories Ltd:
- Net Profit Margin: 9.47%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 3.82% (Industry Average ROCE: 16.11%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 4.27% (Industry Average ROE: 14.47%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.7
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.82
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 178 (Industry average Stock P/E: 45.68)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.05
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 9.47%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | K-56, M.I.D.C. Industrial Area, Palghar District Maharashtra 401506 | auro@aurolabs.com http://www.aurolabs.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sharat Deorah | Chairman & Managing Director |
| Mr. Kiran Suresh Kulkarni | Whole Time Director |
| Mr. Siddhartha Deorah | Whole Time Director |
| Mr. Mahendra Kumar Daga | Ind. Non-Executive Director |
| Mrs. Kavita Vijayakant Sharma | Ind. Non-Executive Director |
| Mr. Vishal Kailashchandra Jhunjhunwala | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Auro Laboratories Ltd?
Auro Laboratories Ltd's intrinsic value (as of 04 November 2025) is 433.96 which is 120.28% higher the current market price of 197.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 123 Cr. market cap, FY2025-2026 high/low of 303/170, reserves of ₹36.74 Cr, and liabilities of 99.09 Cr.
What is the Market Cap of Auro Laboratories Ltd?
The Market Cap of Auro Laboratories Ltd is 123 Cr..
What is the current Stock Price of Auro Laboratories Ltd as on 04 November 2025?
The current stock price of Auro Laboratories Ltd as on 04 November 2025 is 197.
What is the High / Low of Auro Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Auro Laboratories Ltd stocks is 303/170.
What is the Stock P/E of Auro Laboratories Ltd?
The Stock P/E of Auro Laboratories Ltd is 178.
What is the Book Value of Auro Laboratories Ltd?
The Book Value of Auro Laboratories Ltd is 69.0.
What is the Dividend Yield of Auro Laboratories Ltd?
The Dividend Yield of Auro Laboratories Ltd is 0.00 %.
What is the ROCE of Auro Laboratories Ltd?
The ROCE of Auro Laboratories Ltd is 3.85 %.
What is the ROE of Auro Laboratories Ltd?
The ROE of Auro Laboratories Ltd is 4.33 %.
What is the Face Value of Auro Laboratories Ltd?
The Face Value of Auro Laboratories Ltd is 10.0.